Skip to content

Australia Widens PBS Access for Cystic Fibrosis and Blood Cancer

By News Analysis India · · 1 min read

Australia has widened access to subsidised medicines under its Pharmaceutical Benefits Scheme, offering relief to patients with cystic fibrosis, blood cancer, thyroid eye disease and other conditions.

The changes, which came into force on 1 November, were outlined by Health Minister Mark Butler on Sunday.

A key update concerns children with cystic fibrosis aged between 6 and 11 years who weigh under 30 kilograms. These children can now access Trikafta in granule form. The treatment addresses the root cause of this genetic disease and has been developed specifically for young patients who find it hard to swallow pills.

According to the government, nearly 3,300 Australians annually could gain from this expanded coverage.

The government has pointed out that without subsidy, a single prescription for this medicine might cost more than 20,300 Australian dollars, which is about 14,200 US dollars.

Another significant addition is Tepezza, now available under the PBS for active moderate to severe thyroid eye disease. Around 310 patients are expected to benefit every year.

Additionally, subsidised access to Adcetris has been extended. It offers a new initial treatment choice for patients with advanced CD30-positive classical Hodgkin lymphoma, which is a form of blood cancer. Roughly 370 people each year are likely to benefit.

Patients using Repatha, a cholesterol-lowering medicine, can now collect larger quantities at once through the government's 60-day prescription arrangement.

Eligible patients will not pay more than 25 Australian dollars for each PBS prescription, while concession cardholders will pay 7.70 Australian dollars.

Since July 2022, the government has approved extra funding for 511 new and revised medicine listings under the scheme.